Investors in Roche (NASDAQOTH: RHHBY ) and Exelixis (NASDAQ: EXEL )
saw a bit of positive news Monday, when Roche announced that its phase
3 combo study of MEK inhibitor cobimetinib (licensed from Exelixis) and
BRAF inhibitor Zelboraf met it primary endpoint. No details were
supplied, other than that the company is moving forward with regulatory
filings in the U.S. and EU.
Although this combo therapy is not likely to move the needle too far for Roche, it could be significant for Exelixis and talk is now circulating that Roche may buy the company to capture full economics on the drug.
Click here for the full article:
Should Roche Buy Exelixis?
No comments:
Post a Comment